drugset / Trial / NCT00568984

Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

NCT00568984

Phase 4 Completed 324 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes

Timeline

Start
2002-11-21
Primary completion
2003-11-10
Completion
2003-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule
Subject Repaglinide Small molecule
Subject glicazide Unknown